atai Life Sciences to begin human trial for its MDMA derivative EMP-01 to treat PTSD
atai Life Sciences (ATAI) said on Tuesday its Phase 1 study to develop EMP-01 to treat post-traumatic stress disorder (PTSD) had received regulatory and ethics approvals from Medsafe…
atai Life Sciences to begin human trial for its MDMA derivative EMP-01 to treat PTSD
atai Life Sciences (ATAI) said on Tuesday its Phase 1 study to develop EMP-01 to treat post-traumatic stress disorder (PTSD) had received regulatory and ethics approvals from Medsafe…